Swiss Pharmaceuticals & Biotech High Growth Potential Companies

Cosmo Pharmaceuticals

Market Cap: CHF 741.5m

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

Sandoz Group

Market Cap: CHF 13.7b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

SKAN Group

Market Cap: CHF 1.4b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

Galderma Group

Market Cap: CHF 18.1b

Operates as a dermatology company worldwide.

Lonza Group

Market Cap: CHF 37.0b

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

PolyPeptide Group

Market Cap: CHF 481.1m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

Tecan Group

Market Cap: CHF 1.8b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

Bachem Holding

Market Cap: CHF 3.5b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

Roche Holding

Market Cap: CHF 195.4b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Molecular Partners

Market Cap: CHF 119.3m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.